Abbott wins FDA nod for Supera peripheral stent

Abbott says the FDA granted pre-market approval for its Supera stent for treating peripheral artery disease.

Abbott (NYSE:ABT) said the FDA granted pre-market approval for its Supera peripheral stent.

Abbott Park, Ill.-based Abbott said the stent is designed to conform to the shape of patients' blood vessels. The FDA approved the Supera device for treating occlusions in the superficial femoral artery and the proximal popliteal artery.

Food & Drug Administration (FDA), Abbott Laboratories

News Well, Peripheral Stents, Pre-Market Approval (PMA)

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1o8uRsD